Comparison of Different Model Predictions on RBE in the Proton Therapy Technique Using the GATE Code

Authors

Abstract

Recently, proton therapy is used as one of the effective methods for treating various types of cancer in clinical treatment. An appropriate formalism to obtain relative biological effectiveness values for treatment planning studies is needed in this hadrontherapy technique. Hereby, the quantity of biological dose, instead of using the physical doses, is introduced to evaluate the biological effect of radiation in tissue. In proton therapy, a constant RBE of 1.1 is usually applied clinically as recommended by ICRU. However, different studies including data from irradiation experiments propose that a variable RBE factor is more appropriate. The primary objective of this project was to calculate and compare the dose-to-patient results of constant RBE versus variable RBE calculated by different models for hadron therapy. The irradiation experiments show the RBE parameter depends on different parameters such as deposited dose, LET, radiation energy and tissue sensitivity. In the present study, Wilkens, Wedenberg, Carabe and McNamara models were used to calculate RBE and biological dose in different models by using GATE Monte Carlo code. The results of the different models were compared with constant RBE of 1.1. On the other hand, bringing further simulations closer to the real situation, proton beam modulation has been used to create Spread-Out Bragg Peak (SOBP) region, and different models of RBE have been used to calculate the biological doses. Results show that the four different models predicted an equal or lower dose in the proton beam-entrance region compared to predictions for constant RBE, while greatly exceeding the predicted constant RBE dose in the distal part of the region target.

Keywords


[1] D. Schardt, T. Elsasser. Heavy-ion tumor therapy: Physical and radiobiological benefits. Reviews of modern physics, 82, (2010) 383–425. [2] H. Paganetti. Relating proton treatments to photon treatment via the relative biological effectiveness–should we revise current clinical practice. Int J Radiat oncol Bio phys, 91, (2015) 892–894. [3] G. Giovannini, T. Bohlen, G. Cabal, J. Bauer, T. Tessonnier, K. Frey, J. Debus, A. M airani, K. Parodi. Variable RBE in proton therapy: comparison of different model predictions and their influence on clinical-like scenarios. Radiation Oncology, (2016). [4] S. Jan, G. Santin, D. Strul, S. Staelens, D. Autret, et al., GATE: a simulation toolkit for PET and SPECT. Phys Med Biol, 49(19), (2004) 4543-4561. [5] D. E. Lea. Action of radiations on living cells: University Press. Combridge, (1946). [6] T. Sato, Y. Kase, R. Watanabe, K. Niita, L. Sihver. Biological Dose Estimation for Charged-Particle Therapy Using an Improved PHITS Code Coupled with a Microdosimetric Kinetic Model. Radiation Research, 171(1), (2009) 107-117. [7] A.F. Resch, G. Landry, F. Kamp, G. Cabal, C. Belka, J.J. Wilkens, K. Parodi, G. Dedes. Quantification of the uncertainties of a biological model and their impact on variable RBE proton treatment plan optimization. Physica Medica, 36, (2017) 91-102. [8] J.J. Wilkens, U. Oelfke. A phenomenological model for the relative biological effectiveness in therapeutic proton beams. Phys Med Biol, 49(13), (2004) 2811-2825. [9] M. Belli, F. Cera, R. Cherubini, M. Dalla Vecchia, A.M.I. Haque, F. Ianzini, P. Tiveron. RBE-LET relationships for cell inactivation and mutation induced by low energy protons in V79 cells: further results at the LNL facility. International Journal of Radiation Biology, 74(4), (1998) 501-509. [10] M. Folkard, K. M. Prise, B. Vojnovic, H. C. Newman, M. J. Roper, B. D. Michael. Inactivation of V79 cells by low-energy protons, deuterons and helium-3 ions. International Journal of Radiation Biology, 69(6), (1996) 729-738. [11] M. Wedenberg, B. K. Lind, B. Hardemark. A model for the relative biological effectiveness of proton: the tissue specific parameter alpha/beta of photons is a predictor for the sensitivity to LET change. Acta Oncol, 52(3), (2013) 580-588. [12] A. Carabe-Fernandez, R.G. Dale, B. Jones. The incorporation of the concept of minimum RBE (RBE min) into the linear-quadratic model and the potential for improved radiobiological analysis of high-LET treatments. International Journal of Radiation Biology, 83(1), (2007) 27-39. [13] A. L. McNamara, J. Schuemann, H. Paganetti. A phenomenological relative biological effectiveness (RBE) model for proton therapy based on all published in vitro cell survival data. Phys Med Biol, 60(21), (2015) 8399-8416. [14] M. C. Joiner, A. van der Kogel. Basic Clinical Radiobiology, 4th Ed., (2009).